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ABSTRACT
Objective: There is consensus that a more transparent, explicit, and rig-
orous approach to beneﬁt–risk evaluation is required. The objective of this
study is to evaluate the incremental net beneﬁt (INB) framework for
undertaking quantitative beneﬁt–risk assessment by performing a quanti-
tative beneﬁt–risk analysis of alosetron for the treatment of irritable bowel
syndrome from the patients’ perspective.
Methods: A discrete event simulation model was developed to determine
the INB of alosetron relative to placebo, calculated as “relative value-
adjusted life-years (RVALYs).”
Results: In the base case analysis, alosetron resulted in a mean INB of 34.1
RVALYs per 1000 patients treated relative to placebo over 52 weeks of
treatment. Incorporating parameter uncertainty into the model, probabi-
listic sensitivity analysis revealed a mean INB of 30.4 (95% conﬁdence
interval 15.9–45.4) RVALYs per 1000 patients treated relative to placebo
over 52 weeks of treatment. Overall, there was >99% chance that both
the incremental beneﬁt and incremental risk associated with alosetron
are greater than placebo. As hypothesized, the INB of alosetron was
greatest in patients with the worst quality of life experienced at baseline.
The mean INB associated with alosetron in patients with mild, moderate,
and severe symptoms at baseline was 17.97 (-0.55 to 36.23), 29.98
(17.05–43.37), and 35.98 (23.49–48.77) RVALYs per 1000 patients
treated, respectively.
Conclusions: This study demonstrates the potential utility of applying the
INB framework to real-life decision-making, and the ability to use simu-
lation modeling incorporating outcomes data from different sources as a
beneﬁt–risk decision aid.
Keywords: alosetron, beneﬁt–risk analysis, discrete event simulation, irri-
table bowel syndrome.
Introduction
The traditional approach to beneﬁt–risk analysis generally
involves the sequential evaluation of the potential harms and
beneﬁts within the classical statistical (i.e., frequentist) paradigm
of hypothesis testing. From the regulatory perspective, the
mandate of the decision-maker is to review the available evidence
and draw conclusions about the safety and efﬁcacy of a product
in both the pre- and postmarketing phases by considering the
weight of the available evidence. This process does not currently
include, or require, an explicit, transparent quantitative beneﬁt–
risk analysis that facilitates the joint consideration of the poten-
tial harms and beneﬁts and incorporates some measurement of
risk preference. Given the degree of complexity and uncertainty
associated with making trade-offs across multiple harms and
beneﬁts, this decision-making process is not straightforward.
The US Institute of Medicine recommends that researchers
investigate new approaches to conceptualizing, measuring, and
applying beneﬁt–risk analysis, and that the Center for Drug
Evaluation and Research “develop and continually improve a
systematic approach to beneﬁt–risk analysis for use throughout
the US Food and Drug Administration (FDA) in the pre- and
postapproval settings” [1]. The European Medicines Agency’s
Committee for Medicinal Products for Human Use (CHMP)
recommended that the best method would be a structured
approach that explicitly incorporates the importance of beneﬁts
and risks and describes uncertainties and their effect on the
beneﬁt–risk assessment [2]. Although the CHMP currently rec-
ommends a mainly qualitative approach, it also recommends
further research to explore further methodological development.
Thus, there is consensus that a more transparent, explicit, and
rigorous approach to beneﬁt–risk evaluation is required.
Although a number of quantitative methods of beneﬁt–risk
assessment have been proposed, none have been universally
adopted [3–8]. Lynd and O’Brien demonstrated the application
of the incremental net beneﬁt (INB) framework to beneﬁt–risk
analysis in deep-vein thrombosis prophylaxis [9]. More
recently, Garrison et al. also demonstrated the use of the INB
framework for quantitative beneﬁt–risk analysis using a hypo-
thetical decision regarding a new weight loss drug, with
quality-adjusted life-years (QALYs) as the outcome [10].
Further empirical evidence of its application to beneﬁt–risk
analysis is required.
The primary objective of this study was to evaluate the INB
framework for undertaking quantitative beneﬁt–risk assessment
by performing a quantitative beneﬁt–risk analysis of alosetron
for the treatment of irritable bowel syndrome (IBS), from the
patients’ perspective using data available at the time of the regu-
latory beneﬁt–risk decision. Alosetron was chosen for this
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evaluation based on its regulatory history, having been voluntar-
ily withdrawn from the market in November 2000 due to con-
cerns related to potential serious adverse reactions but was
reintroduced in June 2002 after further analysis and extensive
consultation with the US FDA, the implementation of a detailed
risk management plan, and a strong patient lobby [11]. Second-
ary objectives of this study were: 1) to determine the INB of
alosetron relative to placebo from the patients’ perspective over
a 52-week time horizon and 2) to determine if the INB of alose-
tron differs based on symptom severity.
Methods
Using a computer simulation model, the impact of alosetron on
patient’s quality of life was evaluated relative to placebo. The
potential beneﬁts included decreased frequency of abdominal
pain, urgency, and diarrhea, and the primary potential adverse
events were constipation (mild, moderate, and severe), ischemic
colitis, and impacted or perforated bowel. The risk of death
secondary to ischemic colitis and impacted or perforated bowel
was also incorporated into the model based on external obser-
vational data. The primary clinical outcomes pertaining to both
potential harms and potential beneﬁts were derived from patient-
level, premarketing randomized controlled trials (RCTs) in
patients with moderate to severe IBS. Any RCT that evaluated
alosetron 1 mg twice daily for the treatment of IBS in adults
(aged 18 years and over) with at least 12 weeks of treatment, and
where each of these outcomes was recorded daily for the dura-
tion of the trial, was included. Patient-level data from all studies
that met the inclusion criteria were then merged to facilitate a
pooled analysis. All potential outcomes were weighted using
patients’ preferences to facilitate the calculation of INB.
In all included RCTs, patients were required to keep a daily
diary of all IBS-associated symptoms. Adverse events, including
constipation, were only recorded when they occurred. The
number of days a patient reported constipation in a given week
was determined and then classiﬁed as none, mild (1–2 days),
moderate (3–5 days), or severe (>5 days). For ischemic colitis,
and impacted or perforated bowel, the week the adverse event
occurred and the time required for resolution were determined
from the reported data.
Simulation Model
We developed a discrete event simulation model using Arena
version 9.00 (Rockwell Software, Inc., Milwaukee, WI) to cal-
culate the INB of alosetron relative to placebo in a two hypo-
thetical cohorts of 10,000 patients with moderate to severe IBS,
over a 1-year time horizon (Fig. 1). In the base case, one hypo-
thetical patient was randomly assigned speciﬁc baseline charac-
teristics determined from the RCT data (i.e., age, IBS type, and
IBS severity) and then hypothetically exposed to alosetron, while
an identical clone in the other cohort was simultaneously
exposed to placebo (Fig. 1). The base-case analysis was based on
the point estimates of all model parameters including regression
coefﬁcients. The model consisted of 52 1-week cycles resulting in
a 1-year time horizon. Over the time horizon of the model, each
patient experienced improvements and decrements in his or
her health-related quality of life (HRQoL) (i.e., increased or
decreased utility) based on the changes in the frequency of his
or her symptoms and the occurrence of adverse events. Baseline
IBS symptoms were determined based on symptoms reported
during the 2-week pretreatment run-in phase and classiﬁed as
either mild (abdominal pain 5 days per week, urgency 2 days
a week, and diarrhea 2 times a day) or severe (abdominal pain
and urgency 3 days per week and diarrhea 3 times a day);
patients not classiﬁed as mild or severe were deemed to have
moderate symptoms.
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Figure 1 Discrete event simulation model.
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Translating all model outcomes into HRQoL impact facili-
tated the calculation of the INB in “relative value-adjusted life-
years” (RVALYs) [9,10]. RVALYs incorporate both the duration
of time spent in a given health state, and the quality of life (i.e.,
utility or disutility) associated with that health state. Never-
theless, whereas QALYs are generally calculated using von
Neumann–Morgenstern utilities, RVALYs were calculated using
relative utilities derived using conjoint analysis. To calculate the
INB, the net beneﬁt of alosetron and placebo was calculated
separately based on the difference between the mean RVALYs
gained and lost due to beneﬁt and adverse events, respectively.
The mean INB associated with alosetron relative to placebo was
then calculated by subtracting the mean net beneﬁt of placebo
from the mean net beneﬁt of alosetron for each patient pair, and
then averaging over the entire cohort.
Utilities Derived Using Conjoint Preference Weights
The calculation of the INB requires that all potential harms and
beneﬁts be on a common metric (i.e., RVALYs), which is achieved
by incorporating the relative weighting of each outcome. The
multidimensionality and complex interrelationship of the ben-
eﬁts and harms also required that the preference weights be
additive. Therefore, conjoint preference weights (utilities) for IBS
symptoms and potential treatment-related adverse events were
elicited from 565 patients with IBS using a discrete choice experi-
ment (Table 1). Preference weights were scaled between 0 and 1
in which 0 and 1 represent the combination of the best and worst
levels of all attributes, respectively. The conjoint event-speciﬁc
preference weights for each adverse outcome were determined by
converting the preference weights for the different levels of risk
for each probabilistic outcome to a continuous preference weight
by linearly interpolating between categorical risk levels. Ninety-
ﬁve percent conﬁdence intervals (CIs) for the preference weights
were then calculated using the technique proposed by Krinsky
and Robb with 10,000 random draws [12]. The rescaled prefer-
ence weight for each outcome level can be interpreted as the
decrease in utility associated with that outcome.
Extrapolation of Outcomes beyond 12 Weeks
The mean change in utility over the ﬁrst 12 weeks revealed that
symptomatic improvement was greatest in the early weeks and
plateaued by week 12. To incorporate the time dependency of
symptom improvement and the differences between treatments, a
difference model with time-dependent coefﬁcients was ﬁtted to
the 12-week patient-level data for both alosetron and placebo,
such that
ΔU U Sit t t it t i it= + −( ) + +−β β β ε0 1 1 21
where DUit represents the change in utility for patient i in time
interval t relative to time interval t - 1 (i.e., DUit = Uit - Uit-1),
and S is a categorical variable that represents IBS symptoms at
baseline (i.e., mild, moderate, or severe). By deﬁning the baseline
symptoms as a categorical variable, we estimated three different
intercepts for patients with mild, moderate, and severe symp-
toms. With utility as the independent variable, we estimated
time-dependent coefﬁcients (i.e., b0t, b1t, b2t) for each independent
variable in SAS (SAS v.9, Cary, NC). This model was then used to
predict the utility for each patient for weeks 13 to 52. The
regression coefﬁcient for time was not statistically signiﬁcant for
weeks 7 to 12 for either the placebo or alosetron groups, sug-
gesting that the effect of both treatments had plateaued. We
therefore assumed that the estimated regression coefﬁcient for
week 12 was the best predictor of the subsequent 40 weeks in
both groups, which is consistent with previously published data
[13].
Similarly, the decrement in HRQoL associated with constipa-
tion was estimated by ﬁtting a multinomial mixed logit model to
the 12 weeks of patient-level outcome data with severity of
constipation (i.e., mild, moderate, or severe) each week as the
dependent variable, so that
L t age typeit t i i it= + ∗ + ∗ + ∗ +β β β β ε0 1 2 3
where Lit represents the cumulative logit function for mild, mod-
erate, and severe constipation for patient i during time t (where
t = 0–12 weeks), age is age of patient, and type represents IBS
subtype. These models revealed that the risk of constipation
associated with placebo was constant over time, whereas the risk
associated with alosetron increased over the ﬁrst 6 weeks of
treatment and then returned to baseline by week 12, which is also
consistent with previously published data [14]. We therefore
assumed that the risk of constipation in week 12 persisted over
the remaining 40 weeks of the model.
The rate and duration of disutility associated with the
observed serious adverse events were determined directly from
the RCT data. The time to occurrence of both ischemic colitis
and impacted bowel was modeled using a Weibull distribution
over 52 weeks. We assumed that patients experiencing constipa-
tion continued therapy (and therefore continued to experience an
improvement in HRQoL), while patients experiencing colitis and
ischemic bowel discontinued therapy.
No alosetron-related deaths occurred in any premarketing
RCTs. Nevertheless, because of the potential additional increased
risk of ischemic colitis and impacted bowel associated with alos-
etron, and the underlying mortality risk associated with these
events independent of treatment, we included the potential for
mortality associated with each of these events in the model.
Although Wolfe et al. reported two cases of death out of 640
patients receiving alosetron for more than 6 months, neither of
these deaths were attributed to treatment based on the investi-
gators’ judgment [15]. To achieve this, we used the estimated
mortality rate for ischemic colitis of 0.023 (2 out of 84) and for
impacted bowel of 0.015 (2 out of 133) that Ladabaum used [16]
that were derived from FDA documentation (Table 2). Given
their clinical similarities and the potential for misclassiﬁcation,
we assumed that the probability of death associated with severe
constipation was the same as for impacted bowel.
Table 1 Preference weights (scaled to range from 0 to 1) for treatment
outcomes derived using conjoint analysis
Outcome Frequency Disutility* (scaled)
Abdominal pain 1–2 days a week 0.0151
3–5 days a week 0.0378
6–7 days a week 0.0529
Urgency 1–2 days a week 0.0198
3–5 days a week 0.0753
6–7 days a week 0.0817
Diarrhea 1–2 times a day 0.0269
3–4 times a day 0.0827
>4 times a day 0.1042
Constipation 1–2 days a week 0.0143
3–5 days a week 0.0359
6–7 days a week 0.0502
Moderate colitis 0.0177
Severe colitis 0.1258
Impacted bowel 0.0987
Perforated bowel 0.3072
*Disutility equals the utility (i.e., health-related quality of life) decrement associated with a
speciﬁc level of symptoms. For example, a patient with a baseline utility of 0.8 experiences
an episode of severe colitis; their utility would decrease to 0.8 - 0.1258 = 0.6742.
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To evaluate the impact of this uncertainty on the INB, we
incorporated beta distributions around all probabilities and
standard errors for all coefﬁcients from each regression model
into the simulation. A cohort of 10,000 hypothetical patients
and their clones were simulated through the model with one set
of model parameters. This process was repeated 10,000 times,
with new parameter estimates randomly selected from the dis-
tributions for each model parameter each time. The mean net
beneﬁt and INB was then calculated for each iteration of the
model from which the overall mean INB of alosetron relative to
placebo over 10,000 iterations of the model was determined.
The uncertainty in the results associated with variation in
model parameters is illustrated on the incremental risk–beneﬁt
plane [9].
Stratiﬁed and Probabilistic Sensitivity Analysis (PSA)
We hypothesized that the model would demonstrate that alos-
etron results in a greater INB in IBS patients with more severe
baseline symptoms. To test this hypothesis, we stratiﬁed the
simulated cohort based on baseline symptom severity into mild,
moderate, and severe subgroups, and calculated the INB of alos-
etron relative to placebo for each subgroup by running a strata-
speciﬁc model for 10,000 patients in each cohort and comparing
the INB between strata. The mean INB and 95% credibility
interval were determined for each stratiﬁed cohort.
Results
Eighteen phase III RCTs were evaluated and considered for
inclusion in the analysis; seven studies met all inclusion criteria
for this study (S3BA3001, S3BA3002, S3BA2001, S3B20023,
S3B30013, S3BB3001, and S3B23002). Eleven studies were
excluded because abdominal pain (two studies), urgency (one
study), or symptoms (three studies) were not measured daily,
the study was open label (two studies), treatment was <12
weeks (two studies), and one study involved patients <18 years.
From the seven eligible studies, some patients were excluded
due to lack of baseline data (n = 22), no recorded start date for
treatment (n = 9), or no recorded data after baseline (n = 25).
Thus, the ﬁnal analysis includes 1792 patients randomized to
alosetron and 1106 randomized to placebo, providing 18,667
and 11,936 person-weeks of exposure, respectively. Both
groups were comparable with respect to baseline demographics,
IBS subtype, and symptom frequency, and approximately 90%
of the patients in both groups were female (Table 3). There
were three cases of ischemic colitis and two cases of impacted
bowel reported in all alosetron-treated patients over a mean
follow-up of 10.7 weeks, which resolved over 9.3 days and 5
days, respectively. Neither of these outcomes was reported in
the placebo arm of any trial.
In the base-case analysis, alosetron resulted in a mean incre-
mental beneﬁt of 34.9 RVALYs and a mean incremental harm of
-0.8 RVALYs per 1000 patients relative to placebo. Therefore,
the potential beneﬁt of alosetron exceeded the potential harm
(INB 34.1 RVALYs per 1000 patients treated) relative to placebo
over 52 weeks of treatment. In the base case of 10,000 hypo-
thetical patients treated with alosetron (520,000 weeks of
follow-up), constipation occurred in 23,854 (4.6%) weeks (4642
mild, 6833 moderate, and 12,379 severe), and there were 59
cases of impacted bowel (0.11 per 1000 weeks of treatment), 76
cases of ischemic colitis (0.15 cases per 1000 weeks of treat-
ment), and 4 deaths. Conversely, constipation occurred in 4037
(0.8%) weeks in patients receiving placebo (830 mild, 1715
moderate, and 1492 severe cases), and there were no cases of
ischemic colitis, impacted bowel, or death.
PSA revealed a mean incremental beneﬁt of 31.2 (95% CI
16.7–46.2) RVALYs and a mean incremental risk of -0.8 (95%
CI -0.5 to -1.1) RVALYs per 1000 patients treated with alos-
etron relative to placebo. Therefore, the potential beneﬁt of
alosetron exceeded the potential risk with an INB of 30.4 (95%
Table 2 Model parameters
Variable Alostron Placebo Method of derivation or distribution
Change in utility over time as a result of improvement of
symptoms (abdominal pain, urgency, and diarrhea)
DUit = b0t + b1t(1 - Uit-1) + b2tSi + eit Mixed linear regression
Probability of constipation (severe, moderate, and mild) as a
function of time
Logitit = b0i + b1it * t + b2 * age + b3 * IBS_subtype + eit Longitudinal multinomial logit model
Probability of ischemic colitis 3 out of 1792 0 Beta distribution
Probability of impacted bowel 2 out of 1792 0 Beta distribution
Probability of death conditional on ischemic colitis 2 out of 84 0 Weibull distribution
Probability of death conditional on impacted bowel 2 out of 133 0 Weibull distribution
Table 3 Baseline demographics and symptoms of patients from eligible
randomized controlled trials
Placebo
(N = 1106)
Alosetron 1 mg
(N = 1792)
Age [mean (SD)] 45.3 (13.4) 45.5 (13.5)
Sex (female) [n (%)] 960 (86.8%) 1647 (91.9%)
Height (cm) [mean (SD)] 158.9 (25.3) 161.2 (19.3)
Weight (kg) [mean (SD)] 82.4 (29.7) 76.7 (25.7)
Treatment duration (weeks)
Mean (SD) 8.9 (3.7) 8.1 (4.2)
Person weeks of follow-up 11,936 18,667
Ethnicity [n (%)]
Asian 5 (0.5%) 4 (0.2%)
Black 62 (5.6%) 39 (2.2%)
White 1,002 (90.6%) 1,671 (93.2%)
Hispanic 32 (2.9%) 70 (3.9%)
Other 5 (0.5%) 8 (0.4%)
Irritable bowel syndrome subtype
Alternating 489 (44.2%) 623 (34.8%)
Diarrhea 595 (53.8%) 1,130 (63.1%)
Constipation 22 (2.0%) 39 (2.2%)
Frequency of abdominal pain
None 0 0
1–2 days a week 24 (2.2%) 25 (1.4%)
3–5 days a week 329 (29.7%) 501 (28.0%)
6–7 days a week 753 (68.1%) 1,266 (70.6%)
Frequency of urgency
None 14 (1.3%) 38 (2.1%)
1–2 days a week 123 (11.1%) 216 (12.1%)
3–5 days a week 462 (41.8%) 728 (40.6%)
6–7 days a week 507 (45.8%) 810 (45.2%)
Frequency of diarrhea
None 76 (6.9%) 131 (7.3%)
1–2 times a day 660 (59.7%) 1,064 (59.4%)
3–4 times a day 299 (27.0%) 458 (25.6%)
>4 times a day 71 (6.4%) 139 (7.8%)
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CI 15.9–45.4) RVALYs per 1000 patients treated relative to
placebo over 52 weeks of treatment.
The primary etiologic factor contributing to the decrement in
HRQoL (and consequentially RVALYs) with both treatments
was constipation. Averaging over 10,000 iterations of the model
in the probabilistic analysis, constipation occurred in 23,761 of
520,000 (4.6%) weeks of follow-up in the alosetron arm (95%
CI 19,590–28,705) versus 3849 (0.7%) weeks (95% CI 1342–
8844) in the placebo arm. Consistent with the base-case analysis,
on average there were 53 cases of impacted bowel (95% CI
7–139), 83 cases of ischemic colitis (95% CI 18–204), and 3
deaths (95% CI 0–8) associated with these events per 10,000
hypothetical patients treated with alosetron, and no events asso-
ciated with placebo.
The results of the PSA incorporating all second-order uncer-
tainty of model parameters are illustrated in Figure 2 [9]. This
ﬁgure illustrates that there is >99% change that the INB of
alosetron relative to placebo is >0. The results of the PSA can be
further depicted on the risk–beneﬁt plane (Fig. 3). Each point on
the plane represents the mean incremental beneﬁt and risk based
on 10,000 patients simulated with one set of model parameters.
Based on 10,000 sets of randomly selected sets of model param-
eters, essentially, the entire joint density of the distribution of
incremental risk relative to beneﬁt lies in the northeast quadrant
of the risk–beneﬁt plane. If we assume that decision-makers
would trade off HRQoL (i.e., RVALYs) associated with beneﬁt
and risk 1:1, the risk–beneﬁt threshold (m = 1) can be depicted by
a line through the origin in the northeast quadrant that has a
slope of 1. This model therefore implies >99% chance that both
the incremental beneﬁt and incremental risk associated with alos-
etron are greater than placebo. Assuming a risk threshold of
m = 1, there is also >99.9% chance that the INB of alosetron
relative to placebo is below this threshold and therefore favors
the use of alosetron.
As hypothesized, the stratiﬁcation of patients by baseline
quality of life revealed a greater INB associated with alosetron in
patients with more severe symptoms at baseline. The mean INBs
(95% credibility interval) in patients with mild, moderate, and
severe baseline symptoms were 17.97 (-0.55 to 36.23), 29.98
(17.05–43.37), and 35.98 (23.49–48.77) RVALYs per 1000
patients treated, respectively.
Discussion
This study demonstrates the potential utility of applying the INB
framework to real-life decision-making, and the ability to use
simulation modeling incorporating outcomes data from different
sources as a beneﬁt-risk decision aid. Additionally, in this model,
we were able to extrapolate the analysis beyond the follow-up
period of the RCTs.
INB and QALYs have been adopted as the standard for
evaluating the cost-effectiveness of new therapeutic interventions
to help inform reimbursement and insurance decisions [17,18].
Other than data on costs, the data requirements for calculating
the INB for cost-effectiveness or risk-beneﬁt analysis are the
same. Although no speciﬁc methods have been adopted for quan-
titative beneﬁt-risk analysis, it has been recommended that regu-
lators develop, adopt, and improve quantitative approaches [1].
Although many beneﬁt-risk analyses have been published previ-
ously, most have not incorporated an explicit, quantitative
method to simultaneously evaluate potential beneﬁt and risk
[19–24].
This study and others provide empirical evidence supporting
the use of INB without including costs to facilitate more
explicit and transparent regulatory and clinical decision-making
[9,25].
These results are also consistent with the eventual regula-
tory decision that the potential beneﬁts of alosetron outweigh
the potential risks from the perspective of the patient, and
that the INB is greater in IBS patients with more severe
symptoms. Although alosetron was voluntarily withdrawn from
the market due to safety concerns, this was followed by a
strong lobby from patients who had beneﬁted from the drug
for continued access despite safety concerns [26]. This illus-
trates the revealed preferences of at least some IBS patients who
were willing to accept the risk of a serious adverse event in
exchange for potential beneﬁt. Although we would argue
that the regulatory decisions to remove alosetron, and subse-
quently to reintroduce it, were made considering different
risk preferences (e.g., regulator’s vs. patients’), the risk prefer-
Figure 2 Distribution of the mean incremental net beneﬁt of alosetron rela-
tive to placebo derived from the probabilistic sensitivity analysis. RVALYs,
relative value-adjusted life-years.
15 μ = 1
10
5
0
–5
In
cr
em
en
ta
l H
ar
m
 (
R
V
A
LY
s 
Lo
st
pe
r 
10
00
 P
at
ie
nt
s)
0 20 40 60
Incremental Benefit (RVALYs Gained
per 1000 Patients)
Figure 3 Mean incremental harm versus mean incremental beneﬁt of alos-
etron relative to placebo over 52 weeks based on 10,000 patients simulated
10,000 each.Note: line illustrated in the northeast quadrant with slope of m = 1
indicates a beneﬁt–harm trade-off of 1:1. This would be depicted as a 45%
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on the same scale. RVALYs, relative value-adjusted life-years.
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ences applied in the decision-making process were not explicit.
This analysis explicitly incorporates patients’ risk preferences
and therefore only informs a decision from the perspective of
the patient.
This analysis illustrates a number of advantages of using
this beneﬁt-risk modeling approach: 1) all data elements of the
model are explicit and transparent; 2) it provides a quantiﬁca-
tion of the uncertainty surrounding a decision, given the avail-
able data; and 3) it facilitates stratiﬁed analysis to evaluate
differences in INB among different strata. These results are con-
sistent with the US FDA decision to reintroduce alosetron with
an indication restricted to severe IBS, and therefore, it can be
hypothesized that if this model had been available at the time,
the regulatory decision might have been made more expedi-
tiously. Conversely, had the results of this analysis been avail-
able at the time of the initial FDA regulatory review, the initial
approved indication might have been more restrictive, which
might have prevented the need for withdrawal, rereview, and
reintroduction.
This study is somewhat limited by the inability to incorpo-
rate all RCT data into the analysis. Only seven studies met the
inclusion criteria due to the requirement that all outcomes be
measured at all time points over at least 12 weeks. This limi-
tation is a consequence of performing the analysis retrospec-
tively as opposed to planning both the beneﬁt-risk analysis and
the RCTs a priori so that all studies could be included. None-
theless, this proof of concept study aptly demonstrates the fea-
sibility and practicality of using phase III trials to evaluate the
INB.
Regulatory decisions must be made based on phase III RCT
data and are therefore “risk-efﬁcacy” decisions, potentially
resulting in undetected or unmeasured long-term outcomes and
rare events. Although there is no way to evaluate the impact of
any unknown or unanticipated adverse outcomes into an analy-
sis, using a modeling approach, we were able to incorporate
potential anticipated adverse outcomes not directly observed in
the RCTs (i.e., death). Although modeling requires that certain
assumptions be made, the robustness of the model to these
assumptions can be tested in a sensitivity analysis. We assumed
that the beneﬁt of treatment with both alosetron and placebo was
maintained from week 12 to week 52, which is consistent with
one published long-term study [13], and where possible, we
biased the model against alosetron. Despite these potential
biases, the results still favored alosetron.
This analysis illustrates the utility of a modeling application
of INB following phase III; however, this methodology could also
be applied in the postmarketing phase using observational, real-
world effectiveness data, if available. Different perspectives (e.g.,
societal) could also be taken, different methods for preference
elicitation could be employed, and different preferences for dif-
ferent types of patients (e.g., mild vs. severe) could be applied,
which could change the results. Given that quantitative evalua-
tion should not be seen as a replacement for expert judgment but
rather viewed as a decision aid, making the elements of the
decision more explicit and transparent, the next steps will be to
continue to develop, apply, and evaluate this methodology, and
for regulators and decision-makers to further evaluate its utility
in decision-making.
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